Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Macrophilones from the Marine Hydroid Macrorhynchia philippina Can Inhibit ERK Cascade Signaling.

Yan P, Ritt DA, Zlotkowski K, Bokesch HR, Reinhold WC, Schneekloth JS Jr, Morrison DK, Gustafson KR.

J Nat Prod. 2018 Jul 27;81(7):1666-1672. doi: 10.1021/acs.jnatprod.8b00343. Epub 2018 Jul 6.

PMID:
29979591
2.

ONC201 kills breast cancer cells in vitro by targeting mitochondria.

Greer YE, Porat-Shliom N, Nagashima K, Stuelten C, Crooks D, Koparde VN, Gilbert SF, Islam C, Ubaldini A, Ji Y, Gattinoni L, Soheilian F, Wang X, Hafner M, Shetty J, Tran B, Jailwala P, Cam M, Lang M, Voeller D, Reinhold WC, Rajapakse V, Pommier Y, Weigert R, Linehan WM, Lipkowitz S.

Oncotarget. 2018 Apr 6;9(26):18454-18479. doi: 10.18632/oncotarget.24862. eCollection 2018 Apr 6.

3.

Author Correction: Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia.

Jiang X, Hu C, Ferchen K, Nie J, Cui X, Chen CH, Cheng L, Zuo Z, Seibel W, He C, Tang Y, Skibbe JR, Wunderlich M, Reinhold WC, Dong L, Shen C, Arnovitz S, Ulrich B, Lu J, Weng H, Su R, Huang H, Wang Y, Li C, Qin X, Mulloy JC, Zheng Y, Diao J, Jin J, Li C, Liu PP, He C, Chen Y, Chen J.

Nat Commun. 2018 Feb 9;9(1):670. doi: 10.1038/s41467-018-02947-0.

4.

Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia.

Jiang X, Hu C, Ferchen K, Nie J, Cui X, Chen CH, Cheng L, Zuo Z, Seibel W, He C, Tang Y, Skibbe JR, Wunderlich M, Reinhold WC, Dong L, Shen C, Arnovitz S, Ulrich B, Lu J, Weng H, Su R, Huang H, Wang Y, Li C, Qin X, Mulloy JC, Zheng Y, Diao J, Jin J, Li C, Liu PP, He C, Chen Y, Chen J.

Nat Commun. 2017 Dec 13;8(1):2099. doi: 10.1038/s41467-017-02290-w. Erratum in: Nat Commun. 2018 Feb 9;9(1):670.

5.

DNA-Targeted Precision Medicine; Have we Been Caught Sleeping?

Reinhold WC, Thomas A, Pommier Y.

Trends Cancer. 2017 Jan;3(1):2-6. doi: 10.1016/j.trecan.2016.11.002.

6.

Temozolomide in the Era of Precision Medicine.

Thomas A, Tanaka M, Trepel J, Reinhold WC, Rajapakse VN, Pommier Y.

Cancer Res. 2017 Feb 15;77(4):823-826. doi: 10.1158/0008-5472.CAN-16-2983. Epub 2017 Feb 3. Review.

7.

Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay.

Ji J, Zhang Y, Redon CE, Reinhold WC, Chen AP, Fogli LK, Holbeck SL, Parchment RE, Hollingshead M, Tomaszewski JE, Dudon Q, Pommier Y, Doroshow JH, Bonner WM.

PLoS One. 2017 Feb 3;12(2):e0171582. doi: 10.1371/journal.pone.0171582. eCollection 2017.

8.

The NCI-60 Methylome and Its Integration into CellMiner.

Reinhold WC, Varma S, Sunshine M, Rajapakse V, Luna A, Kohn KW, Stevenson H, Wang Y, Heyn H, Nogales V, Moran S, Goldstein DJ, Doroshow JH, Meltzer PS, Esteller M, Pommier Y.

Cancer Res. 2017 Feb 1;77(3):601-612. doi: 10.1158/0008-5472.CAN-16-0655. Epub 2016 Dec 6.

9.

Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against Cancer.

Mameri H, Bièche I, Meseure D, Marangoni E, Buhagiar-Labarchède G, Nicolas A, Vacher S, Onclercq-Delic R, Rajapakse V, Varma S, Reinhold WC, Pommier Y, Amor-Guéret M.

Clin Cancer Res. 2017 Apr 15;23(8):2116-2126. doi: 10.1158/1078-0432.CCR-16-0626. Epub 2016 Sep 6.

10.

A replicator-specific binding protein essential for site-specific initiation of DNA replication in mammalian cells.

Zhang Y, Huang L, Fu H, Smith OK, Lin CM, Utani K, Rao M, Reinhold WC, Redon CE, Ryan M, Kim R, You Y, Hanna H, Boisclair Y, Long Q, Aladjem MI.

Nat Commun. 2016 Jun 8;7:11748. doi: 10.1038/ncomms11748.

11.

Current dichotomy between traditional molecular biological and omic research in cancer biology and pharmacology.

Reinhold WC.

World J Clin Oncol. 2015 Dec 10;6(6):184-8. doi: 10.5306/wjco.v6.i6.184.

12.

Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs.

Nogales V, Reinhold WC, Varma S, Martinez-Cardus A, Moutinho C, Moran S, Heyn H, Sebio A, Barnadas A, Pommier Y, Esteller M.

Oncotarget. 2016 Jan 19;7(3):3084-97. doi: 10.18632/oncotarget.6413.

13.

Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60.

Reinhold WC, Sunshine M, Varma S, Doroshow JH, Pommier Y.

Clin Cancer Res. 2015 Sep 1;21(17):3841-52. doi: 10.1158/1078-0432.CCR-15-0335. Epub 2015 Jun 5. Review.

14.

[Bisphosphonates as new anticancer agents?].

Robert J, Reinhold WC.

Bull Cancer. 2015 Apr;102(4):297-9. doi: 10.1016/j.bulcan.2015.02.010. French. No abstract available.

PMID:
26042254
15.

The 15kDa selenoprotein and thioredoxin reductase 1 promote colon cancer by different pathways.

Tsuji PA, Carlson BA, Yoo MH, Naranjo-Suarez S, Xu XM, He Y, Asaki E, Seifried HE, Reinhold WC, Davis CD, Gladyshev VN, Hatfield DL.

PLoS One. 2015 Apr 17;10(4):e0124487. doi: 10.1371/journal.pone.0124487. eCollection 2015.

16.

Alterations of DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity.

Sousa FG, Matuo R, Tang SW, Rajapakse VN, Luna A, Sander C, Varma S, Simon PH, Doroshow JH, Reinhold WC, Pommier Y.

DNA Repair (Amst). 2015 Apr;28:107-15. doi: 10.1016/j.dnarep.2015.01.011. Epub 2015 Feb 11.

17.

Using drug response data to identify molecular effectors, and molecular "omic" data to identify candidate drugs in cancer.

Reinhold WC, Varma S, Rajapakse VN, Luna A, Sousa FG, Kohn KW, Pommier YG.

Hum Genet. 2015 Jan;134(1):3-11. doi: 10.1007/s00439-014-1482-9. Epub 2014 Sep 12. Review. Erratum in: Hum Genet. 2015 May;134(5):509.

18.

NCI-60 whole exome sequencing and pharmacological CellMiner analyses.

Reinhold WC, Varma S, Sousa F, Sunshine M, Abaan OD, Davis SR, Reinhold SW, Kohn KW, Morris J, Meltzer PS, Doroshow JH, Pommier Y.

PLoS One. 2014 Jul 17;9(7):e101670. doi: 10.1371/journal.pone.0101670. eCollection 2014.

19.

Usp7 protects genomic stability by regulating Bub3.

Giovinazzi S, Sirleto P, Aksenova V, Morozov VM, Zori R, Reinhold WC, Ishov AM.

Oncotarget. 2014 Jun 15;5(11):3728-42.

20.

Gene expression correlations in human cancer cell lines define molecular interaction networks for epithelial phenotype.

Kohn KW, Zeeberg BM, Reinhold WC, Pommier Y.

PLoS One. 2014 Jun 18;9(6):e99269. doi: 10.1371/journal.pone.0099269. eCollection 2014.

21.

High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.

Varma S, Pommier Y, Sunshine M, Weinstein JN, Reinhold WC.

PLoS One. 2014 Mar 26;9(3):e92047. doi: 10.1371/journal.pone.0092047. eCollection 2014.

22.

Commentary on "MelanomaDB: a web tool for integrative analysis of melanoma genomic information to identify disease-associated molecular pathways".

Reinhold WC.

Front Genet. 2013 Aug 13;4:156. doi: 10.3389/fgene.2013.00156. eCollection 2013. No abstract available.

23.

The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.

Abaan OD, Polley EC, Davis SR, Zhu YJ, Bilke S, Walker RL, Pineda M, Gindin Y, Jiang Y, Reinhold WC, Holbeck SL, Simon RM, Doroshow JH, Pommier Y, Meltzer PS.

Cancer Res. 2013 Jul 15;73(14):4372-82. doi: 10.1158/0008-5472.CAN-12-3342. Epub 2013 Jul 15.

24.

Tumor suppressor miR-375 regulates MYC expression via repression of CIP2A coding sequence through multiple miRNA-mRNA interactions.

Jung HM, Patel RS, Phillips BL, Wang H, Cohen DM, Reinhold WC, Chang LJ, Yang LJ, Chan EK.

Mol Biol Cell. 2013 Jun;24(11):1638-48, S1-7. doi: 10.1091/mbc.E12-12-0891. Epub 2013 Apr 3.

25.

USP7 and Daxx regulate mitosis progression and taxane sensitivity by affecting stability of Aurora-A kinase.

Giovinazzi S, Morozov VM, Summers MK, Reinhold WC, Ishov AM.

Cell Death Differ. 2013 May;20(5):721-31. doi: 10.1038/cdd.2012.169. Epub 2013 Jan 25.

26.

Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents.

Zoppoli G, Regairaz M, Leo E, Reinhold WC, Varma S, Ballestrero A, Doroshow JH, Pommier Y.

Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):15030-5. doi: 10.1073/pnas.1205943109. Epub 2012 Aug 27.

27.

Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFβ interaction.

Cunningham L, Finckbeiner S, Hyde RK, Southall N, Marugan J, Yedavalli VR, Dehdashti SJ, Reinhold WC, Alemu L, Zhao L, Yeh JR, Sood R, Pommier Y, Austin CP, Jeang KT, Zheng W, Liu P.

Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14592-7. doi: 10.1073/pnas.1200037109. Epub 2012 Aug 21.

28.

Entry tropism of BK and Merkel cell polyomaviruses in cell culture.

Schowalter RM, Reinhold WC, Buck CB.

PLoS One. 2012;7(7):e42181. doi: 10.1371/journal.pone.0042181. Epub 2012 Jul 31.

29.

CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set.

Reinhold WC, Sunshine M, Liu H, Varma S, Kohn KW, Morris J, Doroshow J, Pommier Y.

Cancer Res. 2012 Jul 15;72(14):3499-511. doi: 10.1158/0008-5472.CAN-12-1370.

30.

Exclusion of the 750-kb genetically unstable region at Xq27 as a candidate locus for prostate malignancy in HPCX1-linked families.

Kouprina N, Lee NC, Pavlicek A, Samoshkin A, Kim JH, Lee HS, Varma S, Reinhold WC, Otstot J, Solomon G, Davis S, Meltzer PS, Schleutker J, Larionov V.

Genes Chromosomes Cancer. 2012 Oct;51(10):933-48. doi: 10.1002/gcc.21977. Epub 2012 Jun 26.

31.

Gene expression profiles of the NCI-60 human tumor cell lines define molecular interaction networks governing cell migration processes.

Kohn KW, Zeeberg BR, Reinhold WC, Sunshine M, Luna A, Pommier Y.

PLoS One. 2012;7(5):e35716. doi: 10.1371/journal.pone.0035716. Epub 2012 May 3.

32.

Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap Trios, and relation to fragile site location.

Ruan X, Kocher JP, Pommier Y, Liu H, Reinhold WC.

PLoS One. 2012;7(2):e31628. doi: 10.1371/journal.pone.0031628. Epub 2012 Feb 9.

33.

Identification of a predominant co-regulation among kinetochore genes, prospective regulatory elements, and association with genomic instability.

Reinhold WC, Erliandri I, Liu H, Zoppoli G, Pommier Y, Larionov V.

PLoS One. 2011;6(10):e25991. doi: 10.1371/journal.pone.0025991. Epub 2011 Oct 10.

34.

Genome-wide depletion of replication initiation events in highly transcribed regions.

Martin MM, Ryan M, Kim R, Zakas AL, Fu H, Lin CM, Reinhold WC, Davis SR, Bilke S, Liu H, Doroshow JH, Reimers MA, Valenzuela MS, Pommier Y, Meltzer PS, Aladjem MI.

Genome Res. 2011 Nov;21(11):1822-32. doi: 10.1101/gr.124644.111. Epub 2011 Aug 3.

35.

CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute.

Zoppoli G, Solier S, Reinhold WC, Liu H, Connelly JW Jr, Monks A, Shoemaker RH, Abaan OD, Davis SR, Meltzer PS, Doroshow JH, Pommier Y.

Oncogene. 2012 Jan 26;31(4):403-18. doi: 10.1038/onc.2011.283. Epub 2011 Jul 18. Erratum in: Oncogene. 2012 Jan 26;31(4):535-6.

PMID:
21765476
36.

G4 motifs correlate with promoter-proximal transcriptional pausing in human genes.

Eddy J, Vallur AC, Varma S, Liu H, Reinhold WC, Pommier Y, Maizels N.

Nucleic Acids Res. 2011 Jul;39(12):4975-83. doi: 10.1093/nar/gkr079. Epub 2011 Mar 3.

37.

Novel regulation of nuclear factor-YB by miR-485-3p affects the expression of DNA topoisomerase IIα and drug responsiveness.

Chen CF, He X, Arslan AD, Mo YY, Reinhold WC, Pommier Y, Beck WT.

Mol Pharmacol. 2011 Apr;79(4):735-41. doi: 10.1124/mol.110.069633. Epub 2011 Jan 20.

38.
39.

mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities.

Liu H, D'Andrade P, Fulmer-Smentek S, Lorenzi P, Kohn KW, Weinstein JN, Pommier Y, Reinhold WC.

Mol Cancer Ther. 2010 May;9(5):1080-91. doi: 10.1158/1535-7163.MCT-09-0965. Epub 2010 May 4.

40.

Exon array analyses across the NCI-60 reveal potential regulation of TOP1 by transcription pausing at guanosine quartets in the first intron.

Reinhold WC, Mergny JL, Liu H, Ryan M, Pfister TD, Kinders R, Parchment R, Doroshow J, Weinstein JN, Pommier Y.

Cancer Res. 2010 Mar 15;70(6):2191-203. doi: 10.1158/0008-5472.CAN-09-3528. Epub 2010 Mar 9.

41.

Multifactorial regulation of E-cadherin expression: an integrative study.

Reinhold WC, Reimers MA, Lorenzi P, Ho J, Shankavaram UT, Ziegler MS, Bussey KJ, Nishizuka S, Ikediobi O, Pommier YG, Weinstein JN.

Mol Cancer Ther. 2010 Jan;9(1):1-16. doi: 10.1158/1535-7163.MCT-09-0321. Epub 2010 Jan 6.

42.

Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity.

Pfister TD, Reinhold WC, Agama K, Gupta S, Khin SA, Kinders RJ, Parchment RE, Tomaszewski JE, Doroshow JH, Pommier Y.

Mol Cancer Ther. 2009 Jul;8(7):1878-84. doi: 10.1158/1535-7163.MCT-09-0016. Epub 2009 Jul 7.

43.

CellMiner: a relational database and query tool for the NCI-60 cancer cell lines.

Shankavaram UT, Varma S, Kane D, Sunshine M, Chary KK, Reinhold WC, Pommier Y, Weinstein JN.

BMC Genomics. 2009 Jun 23;10:277. doi: 10.1186/1471-2164-10-277.

44.

DNA fingerprinting of the NCI-60 cell line panel.

Lorenzi PL, Reinhold WC, Varma S, Hutchinson AA, Pommier Y, Chanock SJ, Weinstein JN.

Mol Cancer Ther. 2009 Apr;8(4):713-24. doi: 10.1158/1535-7163.MCT-08-0921.

45.

Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines.

Lorenzi PL, Llamas J, Gunsior M, Ozbun L, Reinhold WC, Varma S, Ji H, Kim H, Hutchinson AA, Kohn EC, Goldsmith PK, Birrer MJ, Weinstein JN.

Mol Cancer Ther. 2008 Oct;7(10):3123-8. doi: 10.1158/1535-7163.MCT-08-0589.

46.

MicroRNAs modulate the chemosensitivity of tumor cells.

Blower PE, Chung JH, Verducci JS, Lin S, Park JK, Dai Z, Liu CG, Schmittgen TD, Reinhold WC, Croce CM, Weinstein JN, Sadee W.

Mol Cancer Ther. 2008 Jan;7(1):1-9. doi: 10.1158/1535-7163.MCT-07-0573. Epub 2008 Jan 9.

47.

AffyProbeMiner: a web resource for computing or retrieving accurately redefined Affymetrix probe sets.

Liu H, Zeeberg BR, Qu G, Koru AG, Ferrucci A, Kahn A, Ryan MC, Nuhanovic A, Munson PJ, Reinhold WC, Kane DW, Weinstein JN.

Bioinformatics. 2007 Sep 15;23(18):2385-90. Epub 2007 Jul 27.

PMID:
17660211
48.

Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study.

Shankavaram UT, Reinhold WC, Nishizuka S, Major S, Morita D, Chary KK, Reimers MA, Scherf U, Kahn A, Dolginow D, Cossman J, Kaldjian EP, Scudiero DA, Petricoin E, Liotta L, Lee JK, Weinstein JN.

Mol Cancer Ther. 2007 Mar;6(3):820-32. Epub 2007 Mar 5.

49.

Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells.

Reinhold WC, Reimers MA, Maunakea AK, Kim S, Lababidi S, Scherf U, Shankavaram UT, Ziegler MS, Stewart C, Kouros-Mehr H, Cui H, Dolginow D, Scudiero DA, Pommier YG, Munroe DJ, Feinberg AP, Weinstein JN.

Mol Cancer Ther. 2007 Feb;6(2):391-403. Epub 2007 Feb 1.

50.

Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells.

Lorenzi PL, Reinhold WC, Rudelius M, Gunsior M, Shankavaram U, Bussey KJ, Scherf U, Eichler GS, Martin SE, Chin K, Gray JW, Kohn EC, Horak ID, Von Hoff DD, Raffeld M, Goldsmith PK, Caplen NJ, Weinstein JN.

Mol Cancer Ther. 2006 Nov;5(11):2613-23. Epub 2006 Nov 6.

Supplemental Content

Loading ...
Support Center